Global pharmaceutical major Lupin Limited (Lupin) announced signing of an agreement to acquire all rights to two inhalation medicines, Brovana (arformoterol tartrate) Inhalation Solution and Xopenex HFA (levalbuterol tartrate) Inhalation Aerosol, from Sunovion Pharmaceuticals Inc. (Sunovion) for a purchase price of $75 million. The acquisition of these two brands expands Lupin’s portfolio of inhalation products…
Global pharma major Lupin Limited (Lupin) announced the appointment of Dr. Shahin Fesharaki as Global Chief Scientific Officer. Dr. Fesharaki will be responsible for Lupin’s global research and development efforts across branded, generics and specialty products, a statement said. Commenting on the appointment, Vinita Gupta, CEO and Nilesh Gupta, MD, Lupin said, “We are very…
Lupin Limited (Lupin), a global pharmaceutical company has collaborated with Accenture to enable its data driven transformation journey for improved business agility, performance, and operational efficiency. Accenture deployed a digital platform based on SAP S/4HANA, providing decision makers with real-time visibility into integrated data from multiple sources including supply chain, people and sales networks spread across…
Global pharma major Lupin Limited (Lupin) announced the appointment of Diana Amador-Toro as Senior Vice President, Global Compliance. Diana will be responsible for leading Lupin’s Global Compliance function including Training, Internal Audit, and Investigations. She will be based in Lupin’s Somerset office in New Jersey, USA. Diana is a senior leader with more than 38…
Global pharma major Lupin Limited (Lupin) announced the completion of the acquisition of a portfolio of brands from Anglo-French Drugs & Industries Limited (AFDIL) and its Associates. The acquisition will strengthen Lupin’s India Formulation business by adding a fast-growing portfolio of vitamins, minerals, supplements and neurological products. The acquisition of the AFDIL brands takes Lupin…
Global pharma major, Lupin Limited (Lupin) announced changes to its executive team with Dr. Fabrice Egros assuming responsibilities for Global Corporate Development as President, Corporate Development and Growth Markets. Dr. Egros takes over the Corporate Development role from Alan Butcher departing from the Company on February 28, 2022. Dr. Egros will lead the development and…
Global pharma major Lupin Limited (Lupin) announced the launch of its Digital Asthma Educator platform. The platform guides asthma patients on the correct technique of using inhalers. The new platform is the latest initiative under Lupin’s long running umbrella programme, Joint Airways Initiative (JAI), for patients suffering from respiratory ailments. According to estimates, India has…
Global pharma major, Lupin Limited (Lupin) announced that it has signed a royalty-free, limited, non-exclusive voluntary licensing agreement with Eli Lilly and Company (Lilly) for manufacturing and selling of Lilly’s drug Baricitinib in India. Lilly has received permission from Central Drugs Standard Control Organization (CDSCO), Ministry of Health, for restricted emergency use of Baricitinib in…
Ajay Bharwani, Global Head – IT & Technical Applications, Lupin has joined Writer Corporation as Group CIO & Head – Digital Transformation, according to ETCIO report. Bharwani will be based out of Mumbai and report to the organisation’s Chief Corporate Services Officer. In the new role, Bharwani will be responsible for leading the group’s technology…
Lupin Limited (Lupin), global pharmaceutical company, announced the appointment of Mark D. McDade as an Independent Director effective January 28, 2021. McDade is the co-Founder and Partner at Qiming Venture Partners, USA where he led several high-value investments in biotherapeutics, including cell and gene therapy and digital health. With a career spanning over 37 years,…
Pharma major Lupin Limited announced the launch of its Favipiravir in India under the brand name Covihalt for the treatment of mild to moderate COVID-19. Favipiravir has received authorization from the Drug Controller General of India (DCGI) for emergency use, the company mentioned in its press note. Lupin’s Covihalt dosage strength has been developed keeping…
Lupin Limited, an innovation-led transnational pharmaceutical company headquartered in Mumbai, announced the receipt of the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (U.S. FDA) after closure of the inspection for its Vizag facility. The inspection for the API facility was conducted by the U.S. FDA between January 13, 2020 and…
Pharma major Lupin Limited announced the successful close out of the inspection carried out by the Medicines and Healthcare products Regulatory Agency (MHRA), the regulatory agency of the United Kingdom (UK), at its three manufacturing units in Pithampur (India). The inspection for the three units at Pithampur (Unit I, Unit II and Unit III) was…
Pharma major Lupin Limited, announced that its corporate social responsibility arm, Lupin Foundation, has won the Indian Drug Manufacturers’ Association (IDMA} Corporate Citizen Award 2019, at the IDMA 58th Annual Day Celebrations held in Mumbai. Lupin was conferred this award in the CSR category ‘Initiative towards Agriculture,’ for its beekeeping project that has directly benefited…
Pharma major Lupin Limited (Lupin) won the Par Excellence Award at the 33rd National Convention on Quality Concept (NCQC), organised by the Quality Circle Forum of India (QCFI). The event was held at liT BHU – Varanasi from November 26-30, 2019. Lupin’s nomination summarised its transformation project to improve the yield and quality of Cefadroxi…